Newron Pharmaceuticals S.p.A. (SWX: NWRN)
Switzerland
· Delayed Price · Currency is CHF 8.57
+0.08 (0.94%)
Sep 4, 2024, 4:36 PM CET
Newron Pharmaceuticals Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -67.53 | -67.53 | -85.55 | -79.98 | -78.23 | -83.36 | Upgrade
|
| Depreciation & Amortization | 6.6 | 6.6 | 6.22 | 5.9 | 5.46 | 5.5 | Upgrade
|
| Other Amortization | 1.49 | 1.49 | 0.72 | 0.61 | 0.64 | 0.71 | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.06 | 0.06 | -0.04 | 0.01 | 1.35 | 1.34 | Upgrade
|
| Loss (Gain) From Sale of Investments | -0.53 | -0.53 | 1.31 | 12.03 | 1.19 | 9.6 | Upgrade
|
| Loss (Gain) on Equity Investments | - | - | - | 0.61 | 0.52 | 0.54 | Upgrade
|
| Stock-Based Compensation | - | - | - | 0.26 | 0.55 | 0.83 | Upgrade
|
| Other Operating Activities | 24.33 | 24.33 | 35 | 15.6 | 7.89 | 2.76 | Upgrade
|
| Change in Accounts Receivable | 0.53 | 0.53 | -4.22 | -1.68 | -3.11 | 9.58 | Upgrade
|
| Change in Inventory | -9.38 | -9.38 | 5.52 | -3.58 | 8.55 | -3.52 | Upgrade
|
| Change in Accounts Payable | 1.4 | 1.4 | -0.84 | 2.49 | -0.71 | 5.06 | Upgrade
|
| Change in Unearned Revenue | 0.7 | 0.7 | 0.63 | -2.69 | 7.88 | -0.99 | Upgrade
|
| Change in Other Net Operating Assets | -2.92 | -2.92 | -5.26 | -1.49 | 2.65 | 4.5 | Upgrade
|
| Operating Cash Flow | -45.25 | -45.25 | -46.51 | -51.92 | -45.37 | -47.45 | Upgrade
|
| Capital Expenditures | -10.78 | -10.78 | -2.21 | -3.61 | -5.85 | -6.01 | Upgrade
|
| Sale (Purchase) of Intangibles | -5.4 | -5.4 | -4.61 | -1.7 | -1.78 | -1.38 | Upgrade
|
| Investment in Securities | 0.84 | 0.84 | 0.54 | -0.44 | -2.15 | -1.9 | Upgrade
|
| Other Investing Activities | - | - | - | - | 0 | 0.06 | Upgrade
|
| Investing Cash Flow | -15.34 | -15.34 | -6.28 | -5.75 | -9.78 | -9.22 | Upgrade
|
| Long-Term Debt Issued | 62.27 | 62.27 | 55.14 | 61.69 | 58.43 | 52.12 | Upgrade
|
| Total Debt Issued | 62.27 | 62.27 | 55.14 | 61.69 | 58.43 | 52.12 | Upgrade
|
| Long-Term Debt Repaid | -3.91 | -3.91 | -3.85 | -2.47 | -2.38 | -1.94 | Upgrade
|
| Total Debt Repaid | -3.91 | -3.91 | -3.85 | -2.47 | -2.38 | -1.94 | Upgrade
|
| Net Debt Issued (Repaid) | 58.36 | 58.36 | 51.29 | 59.21 | 56.05 | 50.19 | Upgrade
|
| Other Financing Activities | 3.74 | 3.74 | - | -0.04 | -0.69 | -0.48 | Upgrade
|
| Financing Cash Flow | 62.1 | 62.1 | 51.29 | 59.18 | 55.36 | 49.71 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.06 | 0.06 | 0.01 | 0.41 | -0.03 | -0.05 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | -0.13 | -0.13 | -0.02 | -0.82 | - | 0.1 | Upgrade
|
| Net Cash Flow | 1.45 | 1.45 | -1.51 | 1.1 | 0.18 | -6.91 | Upgrade
|
| Free Cash Flow | -56.03 | -56.03 | -48.71 | -55.52 | -51.21 | -53.46 | Upgrade
|
| Free Cash Flow Margin | -325.75% | -325.75% | -271.13% | -293.37% | -236.72% | -334.22% | Upgrade
|
| Free Cash Flow Per Share | -0.11 | -0.11 | -0.14 | -0.18 | -0.27 | -0.39 | Upgrade
|
| Cash Interest Paid | 0.4 | 0.4 | 0.56 | 0.37 | 1.33 | 1.81 | Upgrade
|
| Cash Income Tax Paid | - | - | 0.21 | 0.25 | 0.15 | 0.42 | Upgrade
|
| Levered Free Cash Flow | -50.74 | -50.74 | -48.84 | -43.23 | -29.37 | -18.98 | Upgrade
|
| Unlevered Free Cash Flow | -42.79 | -42.79 | -33.94 | -37.13 | -26.34 | -16.3 | Upgrade
|
| Change in Net Working Capital | -4.85 | -4.85 | -7.66 | -2.65 | -17.98 | -30.38 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.